Claims for Patent: 11,617,724

Summary for Patent: 11,617,724

Title:	Topical pharmaceutical compositions
Abstract:	The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Inventor(s):	Sujatha D. SONTI, Joey Roger THOMAS, Jon Lenn, Leandro SANTOS, Justin WHITEMAN, Michael Quinn DOHERTY, Mary BEDARD, Piyush Jain
Assignee:	Dermavant Sciences GmbH , GlaxoSmithKline Intellectual Property Development Ltd
Application Number:	US15/807,682
Patent Claims:	1. A chemically and physically stable topical pharmaceutical oil-in-water emulsion composition consisting of: an active ingredient 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof in an amount of about 0.5% to about 2% by weight, based on the total weight of the composition, an oil phase in an amount of about 5% to about 25% by weight, based on the total weight of the composition, wherein the oil phase is selected from the group consisting of a fatty acid, an ester, an ester of glycerin, a fatty alcohol, a wax, a sterol, a siloxane, a silane, a hydrocarbon, an essential oil, a vegetable oil, a mineral oil, an animal oil, an edible oil and mixtures thereof, a water phase in an amount of about 30% to about 80% by weight, based on the total weight of the composition, a total surfactant content in an amount of greater than 5% to about 15% by weight, based on the total weight of the composition, wherein the total surfactant content consists of one or more non-ionic surfactants, and a dermatologically acceptable excipient selected from the group consisting of an antioxidant, a pH adjusting agent, a preservative, a co-solvent, a chelating agent, a penetration enhancer, a humectant, a viscosity building agent, a fragrance, a colorant and combinations thereof; wherein the oil phase contains <3% of petrolatum; wherein the D90 of the average droplet size of the oil phase is from about 0.5 micron to about 1 micron; wherein the topical pharmaceutical oil-in-water emulsion composition is chemically and physically stable when stored at standard ICH conditions for up to 6 months, achieves delivery to the skin and minimizes systemic exposure of the 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, and wherein the topical pharmaceutical oil-in-water emulsion composition is formulated as a cream, an ointment, a foam, or a lotion. 2. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein when the oil phase contains either mineral oil or petrolatum, then a second oil phase component is present, or wherein when the oil phase contains both mineral oil and petrolatum, then a third oil phase component is present. 3. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase contains ≤2% petrolatum. 4. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the active ingredient is present in an amount from-about 0.1% to about 1% by weight, based on the total weight of the composition. 5. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the antioxidant is present and is selected from the group consisting of propyl gallate, butylated hydroxytoluene, tocopherol, and combinations thereof. 6. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase comprises at least one oil or fat, and wherein the at least one oil or fat is an ester or an ester of glycerin. 7. The topical pharmaceutical oil-in-water emulsion composition according to claim 6, wherein the ester of glycerin is a medium chain triglyceride of a carbon length from six to twelve carbons. 8. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the one or more non-ionic surfactants is selected from the group consisting of ethoxylated fatty alcohol ethers, PEG castor oils, PEG esters, propylene glycol esters, glyceryl esters and derivatives, polymeric ethers, sorbitan derivatives, fatty alcohols, emulsifying waxes, and mixtures thereof. 9. The topical pharmaceutical oil-in-water emulsion composition according to claim 8, wherein the one or more non-ionic surfactants includes at least one ethoxylated fatty alcohol ether. 10. The topical pharmaceutical oil-in-water emulsion composition according to claim 9, wherein the ethoxylated fatty alcohol ether is a mixture of steareth-2 and steareth-20. 11. The topical pharmaceutical oil-in-water emulsion composition according to claim 8, wherein the one or more non-ionic surfactants is a mixture of an ethoxylated fatty alcohol ether and a sorbitan derivative. 12. The topical pharmaceutical oil-in-water emulsion composition according to claim 11, wherein the mixture of an ethoxylated fatty alcohol ether and a sorbitan derivative is a mixture of steareth-2, steareth-20, and polysorbate 80. 13. The topical pharmaceutical oil-in-water emulsion composition according to claim 8, wherein the one or more non-ionic surfactants is a mixture of an ethoxylated fatty alcohol ether, a sorbitan derivative, and a fatty alcohol. 14. The topical pharmaceutical oil-in-water emulsion composition according to claim 13, wherein the mixture of an ethoxylated fatty alcohol ether, a sorbitan derivative and a fatty alcohol is a mixture of steareth-2, steareth-20, polysorbate 80, and cetearyl alcohol. 15. The topical pharmaceutical oil-in-water emulsion composition according to claim 8, wherein the one or more non-ionic surfactants is a mixture of an ethoxylated fatty alcohol ether, a sorbitan derivative, and a non-ionic emulsifying wax. 16. The topical pharmaceutical oil-in-water emulsion composition according to claim 15, wherein the mixture of an ethoxylated fatty alcohol ether, a sorbitan derivative, and a non-ionic emulsifying wax is a mixture of steareth-2, steareth-20, polysorbate 80, and emulsifying wax NF. 17. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the pH adjusting agent is present in an amount of from about 0.01% to about 10% by weight, based on the total weight of the composition. 18. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein D90 of the average droplet size of the oil phase is about 0.5 micron. 19. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the composition is a cream. 20. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase contains ≤1% of petrolatum. 21. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase contains less than 1% of petrolatum. 22. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase is free of petrolatum. 23. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the composition has a uniform emulsion under microscopy. 24. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof is present in an amount of about 1% by weight of the composition. 25. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof is present in an amount of about 0.50% by weight of the composition. 26. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase is selected from the group consisting of an ester, an ester of glycerin, an essential oil, a vegetable oil and mixtures thereof. 27. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the oil phase is present in an amount of about 5% to about 15% by weight, based on the total weight of the composition. 28. The topical pharmaceutical oil-in-water emulsion composition according to claim 1, wherein the water phase is present in an amount of about 55% to about 75% by weight, based on the total weight of the composition. 29. The topical pharmaceutical oil-in-water emulsion composition according to claim 8, wherein the non-ionic surfactant is a mixture of cetearyl alcohol, polysorbate 60, steareth-2, steareth-20, and polysorbate 80. 30. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the pH adjusting agent is present and is a buffer. 31. The topical pharmaceutical oil-in-water emulsion composition of claim 30, wherein the buffer is selected from the group consisting of citrate/citric acid, acetate/acetic acid, phosphate/phosphoric acid, propionate/propionic acid, lactate/lactic acid, ammonium/ammonia, and edetate/edetic acid. 32. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the preservative is present in an amount of about 0.01% to about 2% by weight, based on the total weight of the composition. 33. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the preservative is present and is selected from the group consisting of benzyl alcohol, imidazolidinyl urea, diazolidinyl urea, dichlorobenzyl alcohol, chloroxylenol, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, phenoxyethanol, sorbic acid, benzoic acid, salts thereof, and mixtures thereof. 34. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the co-solvent is present in an amount of about 1% to about 30% by weight, based on the total weight of the composition. 35. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the co-solvent is present in an amount of about 5% to about 20% by weight, based on the total weight of the composition. 36. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the co-solvent is present and is selected from the group consisting of propylene glycol, diethylene glycol monoethyl ether, and a combination thereof. 37. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the antioxidant is present in amount of about 0.001% to about 5% by weight, based on the total weight of the composition. 38. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the antioxidant is present and is selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, propyl gallate, tocopherol polyethylene glycol 1000 succinate, tert-butylhydroquinone, and mixtures thereof. 39. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the one or more non-ionic surfactants includes an emulsifying wax optionally in combination with one or more of ethoxylated fatty alcohol ethers, PEG castor oils, PEG esters, propylene glycol esters, glyceryl esters and derivatives, polymeric ethers, sorbitan derivatives, and fatty alcohols. 40. The topical pharmaceutical oil-in-water emulsion composition according to claim 2, wherein the oil phase contains either mineral oil or petrolatum and a second oil phase component is present, and the second oil phase component is selected from an ester and an ester of glycerin. 41. The topical pharmaceutical oil-in-water emulsion composition according to claim 2, wherein the oil phase contains mineral oil and petrolatum and a third oil phase component is present, and wherein the third oil phase component is selected from an ester and an ester of glycerin. 42. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the co-solvent is present and is selected from the group consisting of alcohols, carboxylic acids, diols, polyols, and esters. 43. The topical pharmaceutical oil-in-water emulsion composition of claim 1, wherein the co-solvent is present and is selected from the group consisting of ethanol, isopropanol, t-butyl alcohol, benzyl alcohol, hexyl alcohol, diethylene glycol monoethyl ether, butylene glycol, diethylene glycol, dipropylene glycol, ethylene glycol, hexylene glycol, pentylene glycol, propylene glycol, tetraethylene glycol, triethylene glycol, tripropylene glycol, polyethylene glycol, glycerol, caprylic/capric triglyceride, cetyl palmitate, coco-caprylate/caprate, cocoglycerides, dibutyl adipate, diisopropyl adipate, ethyl oleate, ethylhexyl cocoate, ethylhexyl hydroxystearate, ethylhexyl palmitate, isopropyl myristate, isopropyl palmitate, lauryl lactate, myristyl lactate, myristyl myristate, octyldodecyl stearoyl stearate, oleyl oleate, propylene glycol dicaprylate/dicaprate, propylene glycol isostearate, propylheptyl caprylate, and propylene carbonate. 44. The topical pharmaceutical oil-in-water emulsion composition according to claim 39, wherein at least about 90% of droplets of the oil phase have a droplet size of 0.5 micron to 0.75 micron. 45. The topical oil-in-water emulsion composition according to claim 1, wherein topical administration of said composition results in an AUC (from time 0 to end of the dosing interval) below 30 ng·h/mL. 46. The topical oil-in-water emulsion composition according to claim 1, wherein topical administration of said composition results in Cmax below 15 ng/ml.